Verrica Pharmaceuticals Settles Litigation, Dormer Labs Halts US Sales of Cantharidin Products
Author: Benzinga Newsdesk | July 01, 2024 07:42am
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. ("Dormer Labs"). As part of the settlement, Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States, including Dormer brands Cantharone (Liquid) and Cantharone Plus.
Posted In: VRCA